A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon (R)) as a structure modifying therapy in osteoarthritis of the hip and knee

Citation
K. Pavelka et al., A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon (R)) as a structure modifying therapy in osteoarthritis of the hip and knee, OSTEO CART, 8(5), 2000, pp. 335-342
Citations number
33
Categorie Soggetti
Rheumatology,"da verificare
Journal title
OSTEOARTHRITIS AND CARTILAGE
ISSN journal
10634584 → ACNP
Volume
8
Issue
5
Year of publication
2000
Pages
335 - 342
Database
ISI
SICI code
1063-4584(200009)8:5<335:A5RCDS>2.0.ZU;2-X
Abstract
Objective: To determine the structure (disease) modifying effect of a glyco saminoglycan polypeptide association complex (GP-C; Rumalon(R)) in patients with knee and hip osteoarthritis (OA). Methods: Double-blind, randomized, placebo-controlled five-year study. Prim ary assessment criterion was change in radiographic joint space width betwe en baseline and follow-up at 5 years. Secondary outcome criteria included L equesne algofunctional index (LAI), pain on passive motion and consumption of non-steroidal antiinflammatory drugs (NSAIDs). The patients received 10 courses of injections of placebo or GP-C 2 mi intramuscularly in 5 years (t wo courses each year). Each course included 15 injections administered twic e weekly. Results: There were 277 patients with knee OA and 117 patients with hip OA. Control and GP-G treated groups were comparable as to sex, age, duration o f disease, body weight, X-ray stage and value of LAI at the baseline. Knee joint space at 5 years decreased 0.37+/-0.08 (mean+/-standard deviation) mm for GP-C and 0.42+/-0.08 mm for placebo groups (P=0.68). Hip joint space a t 5 years decreased 0.21+/-0.08 mm for GP-C and 0.22+/-0.08 mm for placebo groups (P=0.53). In a subset of patients with hip OA, Kellgren-Lawrence gre ater than or equal to 2 and JSW greater than or equal to 1 mm, there was a trend in favor of GPC for lower joint space narrowing in 5 years (P=0.11). In addition, there were no statistical differences between the treatment gr oups in LAI, pain on passive motion and consumption of NSAIDs. Side-effects after GP-C (14.5%) were rare, mild and not more frequent than in the place bo group (15%). Conclusion: We were not able to demonstrate a structure modifying effect of GP-C in OA of the hip or knee. Radiographic progression of OA in both knee and hip OA was lower than expected in both study groups. (C) 2000 OsteoArt hritis Research Society International.